News
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results